Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour.

about

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour.

Item

http://www.wikidata.org/entity/Q55116336

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Successful neoadjuvant peptide ...... creatic neuroendocrine tumour.

@en

Successful neoadjuvant peptide ...... creatic neuroendocrine tumour.

@nl

type

Item

label

Successful neoadjuvant peptide ...... creatic neuroendocrine tumour.

@en

Successful neoadjuvant peptide ...... creatic neuroendocrine tumour.

@nl

prefLabel

Successful neoadjuvant peptide ...... creatic neuroendocrine tumour.

@en

Successful neoadjuvant peptide ...... creatic neuroendocrine tumour.

@nl

P1476

Successful neoadjuvant peptide ...... creatic neuroendocrine tumour.

@en

P2093

Casper H J van Eijck

http://www.w3.org/2001/XMLSchema#string

J Hofland

http://www.w3.org/2001/XMLSchema#string

Jaap J Teunissen

http://www.w3.org/2001/XMLSchema#string

M L F van Velthuysen

http://www.w3.org/2001/XMLSchema#string

Tiago Nunes da Silva

http://www.w3.org/2001/XMLSchema#string

P2860

Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?

ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.

Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases.

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients

P31

scholarly article

P356

10.1530/EDM-18-0015

http://www.w3.org/2001/XMLSchema#string

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Wouter W de Herder

P577

2018-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29675259

http://www.w3.org/2001/XMLSchema#string

P932

5900461

http://www.w3.org/2001/XMLSchema#string